Sagimet Biosciences Inc (NASDAQ:SGMT) has a beta value of 3.63 and has seen 1.22 million shares traded in the last trading session. The company, currently valued at $165.19M, closed the last trade at $5.13 per share which meant it lost -$0.06 on the day or -1.16% during that session. The SGMT stock price is -303.7% off its 52-week high price of $20.71 and 58.48% above the 52-week low of $2.13. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.91 million shares traded. The 3-month trading volume is 1.23 million shares.
The consensus among analysts is that Sagimet Biosciences Inc (SGMT) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.41.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Sporting -1.16% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SGMT stock price touched $5.13 or saw a rise of 6.56%. Year-to-date, Sagimet Biosciences Inc shares have moved -5.35%, while the 5-day performance has seen it change 29.38%. Over the past 30 days, the shares of Sagimet Biosciences Inc (NASDAQ:SGMT) have changed 46.57%. Short interest in the company has seen 1.97 million shares shorted with days to cover at 4.14.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 14.5% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -16.96% off the targeted high while a plunge would see the stock gain -16.96% from current levels.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
Figures show that Sagimet Biosciences Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 22.73% over the past 6 months, with this year growth rate of 41.35%, compared to 17.40% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -16.23% over the past 5 years.
SGMT Dividends
Sagimet Biosciences Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
Insiders own 14.11% of the company shares, while shares held by institutions stand at 70.18% with a share float percentage of 81.71%. Investors are also buoyed by the number of investors in a company, with Sagimet Biosciences Inc having a total of 100.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust . As of Jun 30, 2024 , the former fund manager holds about 2.49% shares in the company for having 763.99 shares of worth $3.92 million while later fund manager owns 408.12 shares of worth $2.09 million as of Jun 30, 2024 , which makes it owner of about 1.33% of company’s outstanding stock.
